Ladarixin, an inhibitor of IL-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: a multicenter, randomized, double-blind, placebo-controlled trial

Academic Article

Publication Date:

2022

Short description:

Ladarixin, an inhibitor of IL-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: a multicenter, randomized, double-blind, placebo-controlled trial / Piemonti, L., Keymeulen, B., Gillard, P., Linn, T., Bosi, E., Rose, L., Pozzilli, P., Giorgino, F., Cossu, E., Daffonchio, L., Goisis, G., Ruffini, P.A., Maurizi, A.R., Mantelli, F., Allegretti, M.. - In: DIABETES, OBESITY AND METABOLISM. - ISSN 1462-8902. - 24:9(2022), pp. 1840-1849. [10.1111/dom.14770]

abstract:

To evaluate the ability of ladarixin, an inhibitor of the CXCR1/2 chemokine receptors (LDX, 400 mg b.i.d for 3 cycles of 14 days on/14 days off) to maintain C-peptide production in adult patients with newly diagnosed type 1 diabetes.

Iris type:

1.1 Articolo in rivista

List of contributors: